Safety and Performance of a Silicone Implant for Fecal Incontinence Treatment (SimplyFI)

NCT ID: NCT05708612

Last Updated: 2025-02-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-04-01

Study Completion Date

2026-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the clinical investigation is to verify that the device under investigation (SimplyFI) is appropriate to significantly improve fecal incontinence in patients in whom its use is indicated.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Fecal Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Implantation of SimplyFI

Long-term non-active implant

Group Type EXPERIMENTAL

Medical Device (SimplyFI)

Intervention Type PROCEDURE

Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Medical Device (SimplyFI)

Implantation a non-active medical device (SimplyFI) for the treatment of chronic fecal incontinence.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both male and female subjects
* Age ≥ 18 years, \<85 years
* Subject has failed standard conservative therapy for fecal incontinence (at least 6 months)
* Subject is a surgical candidate
* Subject is willing and able to cooperate with follow-up examinations
* Subject has been informed of the study procedures and the treatment and has signed an informed consent form and provided authorization to use and disclose information for research purposes.

Exclusion Criteria

* Treatment with another investigational drug or investigational device
* Unable to understand study requirements or is unable to comply with follow-up schedule
* Contraindicated according to the instruction for use of the device
* Pregnancy or nursing, or plans to become pregnant
* History of significant obstructed defecation or other significant chronic defecatory motility disorders
* Current, external full thickness rectal prolapse or vaginal prolapse
* Inflammatory Bowel Disease
* Irritable Bowel Syndrome
* Systemic disease as source of FI (scleroderma, neurologic disorders, Crohn's)
* Active pelvic infection
* Chronic diarrhea
* Medical history of anal, rectal, or colon cancer
* Prior anterior resection of the rectum
* Medical history of pelvic radiation therapy
* Significant scarring of the recto-vaginal septum, a permanent implant in the rectovaginal septum, or a history of recto-vaginal fistula
* Previous anorectal posterior compartment surgery
* History of complex anal fistula
Minimum Eligible Age

18 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

A.M.I. Agency for Medical Innovations GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stefan Riss, Prof. PD Dr.

Role: PRINCIPAL_INVESTIGATOR

Medical University Vienna

José Manuel Devesa Múgica, Dr.

Role: PRINCIPAL_INVESTIGATOR

Hospital Ruber Internacional

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Göttlicher Heiland Krankenhaus

Vienna, , Austria

Site Status RECRUITING

Medical University Vienna

Vienna, , Austria

Site Status RECRUITING

Klinikum Bielefeld Rosenhöhe

Bielefeld, , Germany

Site Status RECRUITING

MVZ Wiesbaden / KD Helios Klinik

Wiesbaden, , Germany

Site Status WITHDRAWN

Hospital Ruber Internacional

Madrid, , Spain

Site Status RECRUITING

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Austria Germany Spain

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

A.M.I. Agency for Medical Innovations (Clinical Affairs)

Role: CONTACT

+43 5522 90505-0

Florian Blab

Role: CONTACT

+43 5522 90505-4062

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Michaela Lechner, Dr.in

Role: primary

Stefan Riss, Prof. PD Dr.

Role: primary

Mathias Löhnert, Prof. Dr.

Role: primary

José Manuel Devesa Múgica, Dr.

Role: primary

Araceli Bellestro Pérez, Dra.

Role: primary

References

Explore related publications, articles, or registry entries linked to this study.

Dawoud C, Devesa JM, Lohnert M, Vicente R, Metwalli SA, Riss S. Artificial sphincter with a new silicone band for treating faecal incontinence: IDEAL 2b prospective multicentre trial. BJS Open. 2025 Sep 8;9(5):zraf112. doi: 10.1093/bjsopen/zraf112.

Reference Type DERIVED
PMID: 41123163 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CIV-AT-23-01-041926

Identifier Type: OTHER

Identifier Source: secondary_id

CI-48-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

SIMPLAAFY Clinical Trial
NCT06521463 ACTIVE_NOT_RECRUITING NA
Genomics of In-Stent Restenosis
NCT00341562 COMPLETED